← All Northwest Biotherapeutics INC filings

Northwest Biotherapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQB
NWBO
Northwest Biotherapeutics INC
10-K: Northwest Biotherapeutics: Year-End Financials and Operational Update
Northwest Biotherapeutics reports on its 2025 fiscal year, detailing operational progress, financial performance, and ongoing clinical development efforts for its DCVax therapies.
OQB
NWBO
Northwest Biotherapeutics INC
10-K: Northwest Biotherapeutics Reports 2024 Results, Highlights Progress on DCVax and Regulatory Milestones
Northwest Biotherapeutics provides an update on its 2024 activities, including progress on its DCVax platform, regulatory submissions, and manufacturing developments.
OQB
NWBO
Northwest Biotherapeutics INC
10-K/A: Northwest Biotherapeutics Amends Annual Report to Include Omitted Information
Northwest Biotherapeutics has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
OQB
NWBO
Northwest Biotherapeutics INC
10-K: Northwest Biotherapeutics Files 10-K, Highlights Progress in Cancer Immunotherapy
Northwest Biotherapeutics reports on its 2023 activities, including the submission of a Marketing Authorization Application for its DCVax-L product in the U.K. and advancements in its manufacturing capabilities.